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Issues remain to be elucidated in the developmental regulation of erythropoiesis. In particular the
role of Fas, a member of the tumor necrosis factor family of receptors despite much work remains
unclear. During erythropoiesis, Fas is expressed at low levels on erythroblasts. For most cell types,
Fas to FasL interaction causes apoptotic cell death via caspase activation. Here, we show that in
humans, early erythroid progenitors are refractory to apoptosis triggered through Fas. Further dur-
ing early human erythropoiesis, Fas triggered caspase activation provides a positive stimulus for
erythroid maturation, and does not alter cellular proliferation or trigger apoptosis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction caspase-3 [14]. Here we show for the ﬁrst time that both cas-Erythropoesis is maintained in part by negative regulation
involving the so-called ‘death receptor’ Fas/FasL [1–4]. Early ery-
throid progenitors such as the CD34+ erythroid burst forming
units (BFU-E) express very low levels of Fas and are resistant to
Fas induced apoptosis [5–7]. Upon further development however,
cell surface Fas expression increases in early erythroblasts and
they become sensitive to Fas-induced apoptosis [1,8]. Partial pro-
tection is provided by high levels of erythropoetin (Epo) upregu-
lating GATA-1, which induces expression of the anti-apoptotic
Bcl-XL [8–10].
However, recent evidence indicates that Fas mediated caspase
activation can positively regulate erythropoiesis. Research has
shown that disruption of caspase-3 function in early erythroid
progenitors inhibits erythropoiesis, with arrest at the pronormo-
blast stage [11–14]. Work has shown that heat shock protein-70
(Hsp-70) controls erythropoesis by blocking GATA-1 cleavage bychemical Societies. Published by E
teases; BFU-E, burst forming
; Hsp-70, heat shock protein-
RAIL, TNF-related apoptosis-
action.
chemistry, McGill University,
Osler Promenade, Montreal,
. Carlile).pase-8 and caspase-9 participate in human erythropoiesis in cul-
ture. Furthermore, we demonstrate that Fas and FasL, but not
TNF-related apoptosis-inducing ligand (TRAIL), provide a positive
stimulus for the maturation of early human erythroid
progenitors.2. Materials and methods
2.1. siRNA and antibodies
Control siRNA against GFP and siRNA to caspase-3 were previ-
ously described [11]. Other siRNAs include Fas (GUGCA-
GAUGUAAACCAAACTT), caspase-8 (CAACAAUAACACUGUCUCCTT)
caspase-9 (ACACCCAGACCAGUGGACATT) (all from Memorial
Sloan-Kettering Cancer Center). Fas (Ab-1) and FasL (Ab-1) and
the agonistic Fas (Ab-2) antibodies came from Oncogene Research
Products (La Jolla, CA). Caspase-3, -8 and -9 antibodies were from
Santa Cruz Biotech (Santa Cruz, CA). Annexin V antibody was
produced by Trevigen (Gaithersburg, MD). Antibodies to CD34,
CD36 and Glycophorin-A (GPA) and ﬂuorescent secondary
antibodies came from Pharmingen (Heidelberg, Germany).2.2. Realtime Polymerase Chain Reaction (rtPCR)
rtPCR was carried out as per the maker’s instructions (Qiagen).lsevier B.V. All rights reserved.
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Human hematopoietic progenitors were isolated and cultured
as described [11]. Brieﬂy, CD34+ cells were cultured as follows:
days 0–3, 10 ng/ml interleukin-3 (IL-3), 10 ng/ml stem cell factor
(SCF); days 3–7, 10 ng/ml IL-3, 10 ng/ml SCF and 2 U/ml Epo; days
7–9, 10 ng/ml SCF and 2 U/ml Epo and after day 9, 2 U/ml Epo.
2.4. Transfection
CD34+ cells were electroporated using a Nucleofector and a hu-
man CD34 cell nucleofector kit (Amaxa Biosystems, Koeln, Ger-
many) as described [11].
2.5. Cell analysis
For assay of Fas or FasL by ELISA, either the Fas Ligand ELISA Kit
or the Fas/APO-1 ELISA Kit was used (both from Oncogene Re-
search Products, La Jolla, CA). Analysis of cell proliferation and
morphology were as described previously [11].
2.6. Caspase activity monitoring
Caspase-3 activity was assayed using the ENZCHEK caspase-3
assay kit with a DEVD-AMC substrate (Molecular Probes, Eugene,
OR) as previously described [11]. Caspase-8 activity was measured
using the CASP8C caspase-8 assay kit with a Ac-IETD-pNa (Sigma)
as per instructions. Caspase-9 activity was assayed using the Cas-
pase-9 colormetric assay kit with LEHD-pNa (Biovision) as per
instructions.
2.7. Apoptosis measurement
Apoptosis was assayed for using the TACS Annexin 5 Kit (TREV-
IGEN, Gaithersburg, MD) as per the manufacturer’s instructions.
CD34 cells grown for 7–9 days and then washed and cultured with-
out cytokines for 6 h provided the positive control. Terminal
deoxynucleotidyl transferase was assayed using the ApoDirect
DNA Fragmentation Assay Kit (BioVision).
2.8. FACS analysis
Facs analysis was carried out as reported previously [11].3. Results
We have previously demonstrated that isolated human CD34+
progenitor cells maintained with the appropriate regimen of cyto-
kines constitute a valid human erythropoiesis model. Normal
developmental stages occur with a large fraction of progenitor cells
(>30%) becoming enucleated reticulocytes, another 30% becoming
orthochromatic normoblasts and the rest are erythroblasts
(Fig. 1A) [11]. We used this system to investigate whether cas-
pase-8 and -9, in addition to caspase-3, are utilized during
erythropoiesis.
To determine if caspase-3 activity was triggered via caspase-8
or-9 CD34+ progenitors were transfected with siRNA to inhibit cas-
pase-8, -9, or –3 on day 0, then cultured and monitored for caspase
activity over time (Fig. 1B). In controls, the caspase activity for all
three caspases are high at day 0 in undifferentiated CD34+ cells
and then rises to a peak at day 3 prior to declining for the rest of
the culture (Fig. 1B). Caspase-3 siRNA treatment reduced peak cas-
pase-3 activity by approximately 50% between days 0 and 10, con-
sistent with the approximate 50% siRNA transfection efﬁciency in
these cells [11]. Caspase-3 activity was also reduced by 50% withsiRNA to caspase-8 and Fas but with siRNA to caspase-9 the reduc-
tion was only 25%. Further, caspase-8 activity was only reduced by
siRNA to caspase-8 and Fas. In contrast caspase-9 activity was re-
duced by caspase-8, -9, and Fas but not with caspase-3 siRNA.
(Fig. 1B). Hence, caspase-8 and Fas are required for both caspase-
9 and -3 activation.
SiRNAs knockdown efﬁciency was conﬁrmed by realtime PCR,
performed 24 h after nucleofection. The 50–60% reduction in
mRNA level is in agreement with this systems previously reported
transfection efﬁciency (Fig. 1C).
This raised the question how is Fas expression affected by Fas
siRNA [5–7]. To answer this we treated cells with Fas siRNA. Fas-
speciﬁc siRNA further reduced Fas’s normally low expression levels
on days 0–4. Also normal Fas expression increases observed by day
5 were delayed and peak Fas expression (day 8) was decreased by
30% (Fig. 2A). However, Fas expression caught up to and exceeded
the control by day 11, possibly due to siRNA dilution and increased
Fas production as the cells proliferate.
Reticulocyte enucleation was used to judge the effect of siRNA
treatment on erythropoiesis (Fig. 2B). Reduced enucleation, com-
parable to that seen in caspase-3 activity (Fig. 1B), was found with
each of the caspase and Fas siRNA treatments.
Decreasing erythroblast enucleation suggested that reduced
caspase activity blocks erythroid maturation. Morphological analy-
sis was used to assess at which developmental stage the block oc-
curs (Fig. 2C). All cultures are identical on day 7. Control cultures
developed into late erythroblasts with a few residual basophilic
blasts. In siRNA-treated cultures, pronormoblasts increase to con-
stitute nearly half of the day 17 culture. Late erythroblasts num-
bers were also reduced 50%. These results suggest a
developmental block at the pronormoblast stage. This is supported
by FACS analysis (Fig. 2D). The early progenitor marker CD34 de-
clined in all cultures, as expected. CD36 expression, however, de-
clined after day 7 in control cultures but it remained high in
siRNA treated cultures. Glycophorin A expression increased in con-
trols, reaching ca. 95% positive cells by day 17, whereas siRNA trea-
ted cells plateaued at 60% positive cells. Hence, CD36 and
glycophorin A expression patterns suggest siRNA treatment retards
culture development.
This suggests that caspase activation is required for erythroid
maturation prior to culture day 7. To test this, Fas siRNA treatment
was applied on day 0, 3 or 7 of culture (Fig. 2E). Maximal erythroid
developmental inhibition required treatment with Fas siRNA on
day 0. Fas siRNAs effect was diminished at day 3 and, not signiﬁ-
cant on day 7, consistent with proerythroblasts caspase activation.
To conﬁrm that caspase-induced apoptosis of erythroid progen-
itors was not involved, we monitored the cultures by Annexin-V
staining. Control and siRNA-treated cultures exhibited no differ-
ences in apoptosis (Fig. 3A). Hence apoptosis was not responsible
for the differences observed between control and siRNA-treated
cultures. This work has conﬁrmed by FACs analysis to monitor
DNA fragmentation using Terminal Deoxynucleotidyl Transferase
(Fig. 3B). Again the control and siRNA treated cultures had no dif-
ferences in the detectable level of DNA fragmentation. We further
assessed the effect of Fas siRNA on the ability of the cells to form
colonies in semi-solid medium. Fas siRNA did not altered the ob-
served numbers of BFU-Es, colony forming unit-erythroids (CFU-
Es), or CFU-GEMMs (granulocyte erythroid monocyte megakaryo-
cytes) present (Fig. 3C). We used agonistic antibody (Fig. 3D) and
different concentrations of FasL (Fig. 3E) to explore the cells sus-
ceptibility to apoptosis triggered by Fas. In both cases, cells at
day 0 were entirely resistant to apoptosis.
During erythropoesis susceptibility to Fas-triggered apoptosis
rose in parallel with levels of Fas (compare Fig. 3D and E with
3F), as previously reported [1,2]. We determined the peak levels
of cell-associated and soluble FasL occurred at day 2 (Fig. 3F),
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Fig. 1. siRNA to caspase enzymes are effective in early erythroblasts. (A) Cells stained with Wright-Giemsa showing pronormoblasts (day 7), pronormoblasts and basophilic
normoblasts (day10), basophilic normoblasts (day 13), orthochromatic normoblasts and enucleated reticulocytes (day15) enucleating, and enucleated reticulocytes and
orthochromatic normoblasts (day17). Scale bar 5 lm. (B) Puriﬁed, human CD34+ cells were transfected at day 0 with siRNA to GFP (Control) or the indicated caspase or Fas
and cultured [11]. Caspase enzyme activity was assayed over time. (C) Representative rtPCR to test the relative efﬁciency of the various siRNAs used. The above are
representative of three or more experiments.
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Fig. 2. siRNA to caspase enzymes and to Fas block erythroid maturation at the pronormoblast stage. CD34+ cultures were transfected with either control siRNA (GFP) or Fas
siRNA (A) and Fas expression monitored. (B) Cultures were scored for enucleated cell percentage (day 17). (C) Cultures were evaluated for cellular morphology (D), and for cell
surface marker expression. The above are representative of three or more experiments. (E) CD34+ Cultures were treated with Fas or with GFP siRNA (Control). Percent
enucleation was evaluated at day 17. Error bars indicate S.D. of cell counts from ﬁve ﬁelds of view per experiment and three experiments.
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Fig. 3. Inhibition of caspase activity does not affect apoptosis and the levels of Fas and FasL change with time in culture. (A) CD34+ cells were transfected with the indicated
siRNAs at day 0 and evaluated for Annexin-V binding (% Apoptotic Cells). For the positive controls, 7-day erythroblast cultures placed in media without cytokines for 24 h. (B)
CD34+ cells were transfected with Fas siRNAs at day 0 and monitored 24 h later for DNA fragmentation by TdT. (C) CD34+ cells were transfected with Fas siRNAs at day 0 and
grown in semi-solid media. (D) CD34+ cells were cultured as normal and challenged at various time points with agonistic antibody for 12 h before being assayed for Annexin-
V binding. (E) CD34+ cells were cultured and challenged for 24 h at various time points with varying concentrations of soluble FasL and monitored for Annexin-V binding. (F)
Fas and FasL levels on cells or in the media were assayed by ELISA and expressed as a percentage of the maximum observed expression. Maximum soluble FasL concentration
observed was 1.5 ng/ml.
852 G.W. Carlile et al. / FEBS Letters 583 (2009) 848–854when Fas expression is low. To test whether soluble FasL stimu-
lates erythropoiesis, we depleted the media of FasL by washing
the cells at 2 day intervals. This decreased the soluble FasL
(Fig. 4A) and retarded cellular development, with ca. 20% of the
culture blocked at the pronormoblast stage (Fig. 4C), resulting in
signiﬁcantly reduced enucleation at day 17 (Fig. 4B). The failure
to completely block development by media depletion may be
due to residual FasL that accumulated over the 2 days of incuba-
tion or to FasL present on the erythroblast surface. FasL depletion
did not alter cellular proliferation (Fig. 4C) or apoptosis (data not
shown). Addition of 1 ng/ml recombinant FasL, restored cultures
to nearly normal erythroid maturation (Fig. 4B and C). Other
death receptors on the surface of erythroid progenitor cells in-clude DR4 and DR5, which bind the ligand, TRAIL [1,15]. However,
TRAIL addition to depleted cultures did not rescue erythroid mat-
uration (Fig. 4D). Although we cannot exclude some redundancy
in the death receptors and the caspases that can fulﬁll the
requirement, clearly Fas/FasL is sufﬁcient to stimulate early ery-
throid development.
4. Discussion
Caspase-3. and caspase-7 activation early in erythropoiesis is
well documented and in mice Fas had been identiﬁed as being
involved, but if this occurred in the human system was un-
clear [3,12]. Using siRNA on our ex vivo human CD34+ erythroid
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Fig. 4. Developmental block produced by media depletion is rescued by FasL addition but not TRAIL. CD34+ cultures were depleted of FasL by washing and resuspending in
fresh media every 2 days. Control cells were resuspended in normal media. (A) FasL was measured by ELISA. Cultures were evaluated for percent enucleation (day 17) (B) and
over time for cellular morphology (C) in parts B and C 1 ng/ml FasL was added after washing to rescue erythroid differentiation. (D) CD34+ cultures were treated as described
for A. except for the addition of the indicated supplements. Cultures were evaluated for percent enucleation (day 17).
G.W. Carlile et al. / FEBS Letters 583 (2009) 848–854 853progenitor cells, we selectively reduced expression of the Fas path-
way to test its involvement in erythroid maturation. Here, we showthat caspase activation via Fas/FasL has a stimulatory effect on ery-
throid maturation.
854 G.W. Carlile et al. / FEBS Letters 583 (2009) 848–854Without caspase activation, erythroblasts do not develop be-
yond the pronormoblast stage, a transition that begins around cul-
ture day 7. However, the pronormoblast block is most effectively
produced by reducing caspase-3 [11] or Fas (Fig. 2) expression be-
fore day 3. At this point, erythroblasts are refractory to apoptosis,
possibly because Fas expression is low. Nevertheless, soluble FasL
engages cell surface Fas and triggers caspase activation because re-
moval of either FasL (by washing) or Fas (using siRNA) reduces cas-
pase activation and blocks erythroid maturation. Notably,
autocrine cytokine depletion can be rescued by FasL but not TRAIL,
another erythroid death receptor ligand.
Studies have reported that Fas/FasL induces erythroblast apop-
tosis. Erythroid homeostasis relies on cytokines including Epo pro-
moting cell survival by inducing the anti-apoptotic Bcl-2 family
proteins [7–10,14,16]. However, FasL expressed on late erythro-
blasts induced apoptosis [1,2]. deMaria found that for Fas-sensitive
erythroblasts two factors decided cell fate; Fas stimulation levels
and Epo concentration for culture maintainence [1]. Sublethal
doses of anti-Fas antibody caused caspase activation and GATA-1
cleavage, but not apoptosis. However, recent work showed that
HSP-70 blocks caspase-3 mediated cleavage of GATA-1 during
erythropoiesis [14]. Nevertheless, culture maturation was inhib-
ited at the basophilic erythroblast stage. This contrasts with our
work and may be due to the early developmental stage at which
we tested our cultures. Fas/caspase depletion only restricts devel-
opment in the ﬁrst days of culturing, corresponding to BFU-E and
CFU-E progenitors. The up-regulation of expression of Fas and FasL
sensitizing early human erythroblasts to apoptosis has only been
shown with high interferon levels [17].
Studies in mouse models have suggested that Fas and FasL play
a negative role in the erythroid regulation. However, our human
erythroblast studies, demonstrate a positive function for the Fas/
caspase signaling pathway in erythropoesis. The reason for this dif-
ference is unclear but may be another example of the difference in
species [18].
Caspase mediated apoptosis is central for organism develop-
ment [19]. However, several instances have been identiﬁed where
caspase activation without apoptosis is implicated in lineage spe-
ciﬁc differentiation. Studies using caspase inhibitors blocked
ex vivo differentiation of lens epithelial cells [20], keratinocytes
[21], megakaryocytes [22] and erythroblasts [11]. We have demon-
strated that caspase activation via Fas/FasL stimulation is required
for erythroid maturation. Furthermore, the stimulatory activity of
caspases in erythroid maturation is transitory and speciﬁc for
CD34+ early erythroid progenitors, despite the low levels of Fas ex-
pressed on these cells. Given that Fas is expressed at low levels on
many different cell types throughout development, it may be thatnon-apoptotic caspase activation has a much broader role in hu-
man development than is currently recognized.
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